JP2018527924A5 - - Google Patents
Info
- Publication number
- JP2018527924A5 JP2018527924A5 JP2018509904A JP2018509904A JP2018527924A5 JP 2018527924 A5 JP2018527924 A5 JP 2018527924A5 JP 2018509904 A JP2018509904 A JP 2018509904A JP 2018509904 A JP2018509904 A JP 2018509904A JP 2018527924 A5 JP2018527924 A5 JP 2018527924A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding protein
- binding fragment
- seq
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 102
- 108091000831 antigen binding proteins Proteins 0.000 claims description 102
- 239000012634 fragment Substances 0.000 claims description 72
- 239000000427 antigen Substances 0.000 claims description 52
- 102000036639 antigens Human genes 0.000 claims description 52
- 108091007433 antigens Proteins 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 241000588748 Klebsiella Species 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 206010061259 Klebsiella infection Diseases 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 238000012575 bio-layer interferometry Methods 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 206010011409 Cross infection Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 208000032376 Lung infection Diseases 0.000 claims description 2
- 208000006816 Neonatal Sepsis Diseases 0.000 claims description 2
- 206010029803 Nosocomial infection Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 206010048038 Wound infection Diseases 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 206010014801 endophthalmitis Diseases 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000002956 necrotizing effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- 241001534216 Klebsiella granulomatis Species 0.000 claims 1
- 241000588749 Klebsiella oxytoca Species 0.000 claims 1
- 206010024652 Liver abscess Diseases 0.000 claims 1
- 241000588746 Raoultella planticola Species 0.000 claims 1
- -1 aminoglycosides Chemical class 0.000 claims 1
- 229940041011 carbapenems Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000012004 kinetic exclusion assay Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 10
- 241000588747 Klebsiella pneumoniae Species 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 101100446843 Klebsiella pneumoniae mrkA gene Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208975P | 2015-08-24 | 2015-08-24 | |
| US62/208,975 | 2015-08-24 | ||
| US201562238828P | 2015-10-08 | 2015-10-08 | |
| US62/238,828 | 2015-10-08 | ||
| PCT/US2016/048221 WO2017035154A1 (en) | 2015-08-24 | 2016-08-23 | Mrka polypeptides, antibodies, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527924A JP2018527924A (ja) | 2018-09-27 |
| JP2018527924A5 true JP2018527924A5 (https=) | 2019-10-03 |
Family
ID=58100831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509904A Pending JP2018527924A (ja) | 2015-08-24 | 2016-08-23 | Ｍｒｋａポリペプチド、抗体、およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170073397A1 (https=) |
| EP (1) | EP3341004A4 (https=) |
| JP (1) | JP2018527924A (https=) |
| KR (1) | KR20180042300A (https=) |
| CN (1) | CN107921086A (https=) |
| AU (1) | AU2016313653A1 (https=) |
| BR (1) | BR112018003252A2 (https=) |
| CA (1) | CA2995387A1 (https=) |
| CL (1) | CL2018000357A1 (https=) |
| CO (1) | CO2018001985A2 (https=) |
| HK (1) | HK1252350A1 (https=) |
| IL (1) | IL257434A (https=) |
| MX (1) | MX2018001964A (https=) |
| RU (1) | RU2018107056A (https=) |
| TW (1) | TW201718626A (https=) |
| WO (1) | WO2017035154A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190077306A (ko) | 2016-08-05 | 2019-07-03 | 메디뮨 엘엘씨 | 항-o2 항체 및 이의 용도 |
| US11117956B2 (en) | 2016-10-19 | 2021-09-14 | Medimmune, Llc | Anti-O1 antibodies and uses thereof |
| WO2018237221A1 (en) * | 2017-06-23 | 2018-12-27 | Nosocomial Vaccine Corporation | IMMUNOGENIC COMPOSITIONS |
| CN115838430A (zh) * | 2022-07-08 | 2023-03-24 | 中国人民解放军陆军军医大学 | 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用 |
| CN116813725B (zh) * | 2023-07-06 | 2025-11-04 | 深圳康泰生物制品股份有限公司 | 肺炎克雷伯菌的FimA的抗原表位肽及其应用 |
| CN119798389A (zh) * | 2024-12-12 | 2025-04-11 | 中国人民解放军军事科学院军事医学研究院 | 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7041465B1 (en) * | 1999-08-11 | 2006-05-09 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| AU7470300A (en) * | 1999-08-11 | 2001-03-05 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| CA2541360A1 (en) * | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| WO2007141274A2 (en) * | 2006-06-06 | 2007-12-13 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
| GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| EP2489673A3 (en) * | 2007-05-02 | 2012-09-12 | Intercell AG | Klebsiella antigens |
| GB0915403D0 (en) * | 2009-09-04 | 2009-10-07 | London School Hygiene & Tropical Medicine | Protein glycosylation |
| WO2011100700A2 (en) * | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| US20140011691A1 (en) * | 2010-10-26 | 2014-01-09 | Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting for and on Behalf of Az. | Morphology and protein specific reagents as diagnostics for neurodegenerative diseases |
| BR112014011028B1 (pt) * | 2011-11-07 | 2021-03-02 | Medimmune, Llc | anticorpo biespecífico, composição, e, uso da composição |
-
2016
- 2016-08-23 HK HK18111635.8A patent/HK1252350A1/zh unknown
- 2016-08-23 AU AU2016313653A patent/AU2016313653A1/en not_active Abandoned
- 2016-08-23 MX MX2018001964A patent/MX2018001964A/es unknown
- 2016-08-23 RU RU2018107056A patent/RU2018107056A/ru not_active Application Discontinuation
- 2016-08-23 EP EP16839995.4A patent/EP3341004A4/en not_active Withdrawn
- 2016-08-23 WO PCT/US2016/048221 patent/WO2017035154A1/en not_active Ceased
- 2016-08-23 TW TW105126946A patent/TW201718626A/zh unknown
- 2016-08-23 BR BR112018003252A patent/BR112018003252A2/pt not_active Application Discontinuation
- 2016-08-23 US US15/244,960 patent/US20170073397A1/en not_active Abandoned
- 2016-08-23 CA CA2995387A patent/CA2995387A1/en not_active Abandoned
- 2016-08-23 KR KR1020187007376A patent/KR20180042300A/ko not_active Withdrawn
- 2016-08-23 JP JP2018509904A patent/JP2018527924A/ja active Pending
- 2016-08-23 CN CN201680047771.3A patent/CN107921086A/zh active Pending
-
2018
- 2018-02-08 CL CL2018000357A patent/CL2018000357A1/es unknown
- 2018-02-08 IL IL257434A patent/IL257434A/en unknown
- 2018-02-23 CO CONC2018/0001985A patent/CO2018001985A2/es unknown
- 2018-03-29 US US15/940,344 patent/US20190062411A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527924A5 (https=) | ||
| JP2022177090A5 (https=) | ||
| JP2021521843A5 (https=) | ||
| JP2020500005A5 (https=) | ||
| JP7160484B2 (ja) | 抗ｏ１抗体およびその使用 | |
| RU2018107056A (ru) | Полипептиды mrka, антитела к ним и пути их применения | |
| CN114729033B (zh) | 抗α-溶血素的抗体及其应用 | |
| ES2426093T3 (es) | Anticuerpo dirigido contra PcrV | |
| CN106496324A (zh) | 一种抗呼吸道合胞病毒的全人源抗体 | |
| JP2020522280A5 (https=) | ||
| US11365240B2 (en) | Anti-HSA antibodies | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP7161266B2 (ja) | 抗ｏ２抗体およびその使用 | |
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| WO2020029860A1 (zh) | 针对狂犬病病毒的双特异性抗体及其用途 | |
| JP2017521054A5 (https=) | ||
| US20260041765A1 (en) | Pharmaceutical composition of pvrig/tigit bispecific antibody and use thereof | |
| CN102690789A (zh) | 分泌破伤风外毒素单克隆抗体的杂交瘤细胞株及由其制备的单克隆抗体、Fab抗体与应用 | |
| IL278323B2 (en) | Antibodies directed against glycoprotein IV | |
| US20260042865A1 (en) | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases | |
| KR20220148198A (ko) | 항-bcma 항체, 이의 약학 조성물 및 응용 | |
| CN111356702A (zh) | 抗pd-l1抗体及其抗原结合片段 | |
| CN101875694B (zh) | TNFα的抗体及其用途 | |
| RU2022107387A (ru) | Межвидовые антитела к латентному tgf-бeta 1 и способы их применения | |
| JPWO2023011338A5 (https=) |